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ABSTRACT
Background: Approximately 10% of patients clinically
diagnosed with early Parkinson’s disease (PD) subse-
quently have normal dopaminergic functional imaging.
Transcranial sonography (TCS) has been shown to
detect midbrain hyperechogenicity in approximately
90% of Parkinson’s disease (PD) patients and 10% of
the healthy population. The aim of this study was to
investigate the prevalence of midbrain hyperechogenic-
ity in patients with suspected parkinsonism and scans
without evidence of dopaminergic deficit (SWEDD), in
comparison to PD patients.
Methods: TCS was performed in 14 patients with
SWEDD and 19 PD patients.
Results: There was a significantly increased area of
echogenicity in the PD group (0.24 6 0.06 cm2), com-
pared to the group of patients with SWEDD (0.13 6
0.06 cm2; P < 0.001). One (9.1%) of these patients,
compared to 14 (82.5%) of the PD patients, was found
to have hyperechogenicity (P < 0.001).
Conclusions: We conclude that TCS is useful to distin-
guish PD patients from patients with suspected parkin-
sonism and SWEDD. VC 2012 Movement Disorder
Society
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Recent clinical trials using [123I]b-CIT single-pho-
ton emission computed tomography (SPECT) and
[18F]-dopa PET as surrogate markers for disease pro-
gression have found that 5.7% to 14.7% of cases
clinically diagnosed as early Parkinson’s disease (PD)
have normal scans (scans without evidence of dopa-
minergic deficit; SWEDD).1,2 In a European multicen-
ter prospective study including diagnostically
uncertain cases and performing FP-CIT-SPECT, the
rate of SWEDD was 21%.3 The proportion of
SWEDD in general practice is currently unknown,
and the significance of normal imaging in patients
with a clinical diagnosis of PD is still debated. There
is growing evidence that these patients suffer from
conditions not affecting the nigrostriatal dopaminer-
gic system and may therefore have different patho-
physiology, prognosis, and treatment requirements.
SWEDD subjects in the ELLDOPA study lacked clini-
cal responsiveness to levodopa,4 and follow-up dopa-
mine transporter (DAT) scans after 4 years remained
normal.5 Recently, it was shown that abnormality in
cortical plasticity, assessed by paired associative stim-
ulation, was markedly different in PD and tremulous
SWEDD.6 Alternative diagnoses have been considered
as essential tremor (ET), depression, vascular or psy-
chogenic parkinsonism, dopa-responsive dystonia,
supranigral parkinsonism,4 and primary adult-onset
dystonic tremor.7–9
Certain clinical features point toward a diagnosis
of tremulous SWEDD, such as lack of true bradyki-
nesia and presence of dystonia or head tremor,
whereas reemergent tremor, true fatiguing or decre-
ment, good response to dopaminergic drugs, and the
presence of nonmotor symptoms favor a diagnosis
of PD.6,10,11 However, clinical distinction of tremu-
lous SWEDD from PD remains difficult in some
cases.12
Hyperechogenic alterations in the area of the mid-
brain have been consistently found in up to 90% of
patients with PD in a variety of studies using trans-
cranial sonography (TCS).13–15 Midbrain hyperecho-
genicity has also been observed in approximately
10% of the healthy population. Recent studies have
suggested an increased risk of developing PD in a
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subgroup of people with midbrain hyperechogenic-
ity.16,17 In addition, midbrain hyperechogenicity has
been associated with the development of PD in
patients with idiopathic REM sleep behavior
disorder.18,19
In the present study, we aimed to investigate the
prevalence of midbrain hyperechogenicity in SWEDD,
in comparison to patients with PD.
Patients and Methods
The study received approval from the local ethics
committees and conformed to the Declaration of
Helsinki. All participants gave written informed
consent.
Subjects
Of a total of 34 SWEDD patients observed between
April 2007 and September 2009 in two movement
disorder centers, 14 agreed to participate in the pres-
ent study (8 from the Department of Neurology, Uni-
versity College London [UCL; London, UK] and 6
from the Department of Neurology, Medical Univer-
sity Innsbruck [Innsbruck, Austria]). All had a clini-
cal suspected diagnosis of PD made by a neurologist
and a subsequent normal DAT-SPECT scan ([123I]FP-
CIT: n ¼ 11; [123I]ß-CIT: n ¼ 3). We additionally
recruited 19 consecutive patients with a diagnosis of
PD according to UK Brain Bank Criteria and abnor-
mal [123I]FP-CIT SPECT scans. Striatal FP-CIT
uptake was quantified by measuring the striatal/pos-
terior lobe binding. Striatal binding of [123I]FP-CIT
(putaminal binding of [123I]ß-CIT) was considered
normal when the absolute tracer accumulation was
>2.5 (>7.8) or the side-to-side difference of [123I]FP-
CIT was >0.15. In both centers, patients with
SWEDD had normal scans, as defined by the criteria
above.20,21
Demographic and clinical data of patients are sum-
marized in Table 1.
Sonography
TCS was performed using a 2.5-MHz transducer
(Logiq 7; General Electric, Milwaukee, WI) from both
sides using the acoustic temporal bone window. All
SWEDD and PD patients were examined by the same
experienced sonographer (H.S.) who was blinded to
the diagnosis. TCS was performed in a random order
and patients were lying in the supine position, covered
with a blanket up to the neck, before the blinded in-
vestigator entered the darkened room. For analysis,
only subjects were included for whom the typical but-
terfly-shaped mesencephalon was clearly displayed.
Images of TCS examinations were stored digitally and
were used for the segmentation procedure, as
described previously.13,18
To compare areas of echogenicity and the preva-
lence of hyperechogenicity between groups, the side
of the midbrain with the greater area of echogenicity
(right or left) of each subject was used for statistical
comparison between groups. Hyperechogenicity of
the area of SN was defined as an area of echogenic
signal of 0.20 cm2 or greater on at least one side.
This value corresponds to the 90th percentile of the
area of echogenicity in the SN region of a popula-
tion-based cohort of healthy individuals 50 years of
age and above, who had been investigated by the
same TCS examiner (H.S.), as described
previously.18
Statistical Analysis
Data were tabulated and analyzed using SPSS
15.0 for Windows (SPSS, Inc., Chicago, IL).
Table 1. Demographic data, clinical data, TCS results of
study patients, and diagnostic accuracy of midbrain
hyperechogenicity for the differential diagnosis of PD
versus SWEDD
Demographic and
Clinical Data PD Patients
SWEDD
Patients
PD Versus
SWEDD
Patients, n 19 14
Female/male, n 7:12 7:7 0.497
Age, years
(mean 6 SD)
63.3. 6 7.5 68.2 6 10.8 0.130
Age at onset, years
(mean 6 SD)
55.4 6 11.8 56.3 6 11.8 0.830
Disease duration, years
(mean 6 SD)
7.5 6 7.2 14.9 6 11.3 0.030*
DAT-SPECT after
disease onset,
years (mean 6 SD)
7.2 6 9.3 7.5 6 7.9 0.900
Sufficient bone
window, n (%)
17 (89.5) 11 (78.5) 0.630
Midbrain
hyperechogenicity,
n (%)
14 (82.5) 1 (9.1) <0.001*
UPDRS motor score,
mean 6 SD
18 6 10 10.8 6 3.7 0.020*
Sensitivity, % 82.4 (58.2–94.6)
Specificity, % 90.9 (60.1–99.9)
PPV, % 93.3 (68.2–99.9)
NPV, % 76.9 (49.1–92.5)
Overall accuracy, % 85.7 (67.9–94.9)
Likelihood ratio 9.06
TP, n 14
FP, n 1
FN, n 3
TN, n 10
Data in parentheses are the confidence intervals.
*Significance level: P < 0.05.
Abbreviations: TP, true positive; FP, false positive; FN, false negative; TN,
true negative.
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Because echogenic areas of the SN were not nor-
mally distributed, as demonstrated by Shapiro-
Wilks’ test, Mann-Whitney’s U test was applied
for statistical comparisons of areas of echogenic
signals in the SN between groups. Group compar-
ison of the prevalence of hyperechogenic signal in
the SN region was performed by the chi-square
test for categorical variables. Between compari-
sons were performed with two-tailed unpaired t
tests and Fisher’s exact tests. The significance
level was set at P < 0.05. Results are reported as
means 6 standard deviation (SD; median). In
addition, the diagnostic accuracy of midbrain
hyperechogenicity for the diagnosis of PD was
calculated.
Results
Seventeen (89.5%) PD patients and 11 (78.5%)
SWEDD patients had a sufficient acoustic temporal
bone window for TCS investigation. No significant
difference of area of echogenic signal was found
between male and female subjects in either group.
There was a significantly increased area of echogenic-
ity in the SN region in the PD group, compared to the
SWEDD group (P < 0.001). Mean size of echogenic
area of SWEDD patients was 0.13 6 0.06 cm2 (me-
dian, 0.14), compared to 0.24 6 0.06 cm2 (median,
0.25) in patients with PD (P < 0.001) (see Fig. 1).
One SWEDD patient (9.1%) was found to have mid-
brain hyperechogenicity defined as an area of echo-
genic signal of 0.20 cm2 or greater on at least one
side, as compared to 14 (82.5%) of the PD patients
(P < 0.001).
For diagnostic accuracy of midbrain hyperechogenic-
ity for the differential diagnosis of PD versus SWEDD,
see Table 1.
Discussion
The clinical diagnosis of PD can be challenging in
the early stage and when patients present with subtle
or ambiguous signs.
In a number of studies, midbrain hyperechogenicity
in the area of the SN has been a consistent finding in
up to 90% of patients with idiopathic PD.13–15 A
recent prospective study on a cohort of patients with
different types of parkinsonism has suggested a sensi-
tivity of 90.7% and a specificity of 82.4% of midbrain
hyperechogenicity on TCS for a diagnosis of idio-
pathic PD (iPD).22
In this study, only 1 (9.1%) of the SWEDD patients
was found to have midbrain hyperechogenicity. In our
PD group, we detected midbrain hyperechogenicity in
82.5%. This is in line with previous studies that
reported midbrain hyperechogenicity in PD patients.13
The overall diagnostic accuracy of TCS in distinguish-
ing PD from SWEDD was 85%.
Observer bias is unlikely to explain these different
rates, because measurements of echogenicity were
performed by an experienced sonographer, who was
not involved in the clinical care or assessment of the
patients and was kept blinded for their imaging find-
ings as well as for their clinical presentation. Further-
more, SWEDD patients entered the study because of
the presence of clinical signs suggestive of PD, mak-
ing the distinction between the groups during a brief
examination with the patient lying supine very
unlikely.
The present study provides further evidence that
most SWEDD patients do not have PD because their
midbrain echogenicity was in the same range as in
control subjects, and therefore SWEDDs and PD most
likely have a different underlying pathophysiology.
The normal DAT-SPECT scans in patients with sus-
pected PD prompted us to seek for alternative diagno-
ses, and on follow-up, new working diagnoses
included adult-onset dystonic tremor (n ¼ 6), essential
tremor (n ¼ 4), psychogenic parkinsonism (n ¼ 2),
atypical tremor (n ¼ 1), and vascular parkinsonism (n
¼ 1).
Recent studies found that the extent of hypere-
chogenicity did not correlate with the degeneration
of presynaptic dopaminergic nerve terminals in
patients with PD, concluding that hyperechogenic-
ity and degeneration of presynaptic dopaminergic
nerve terminals exist independently from each
other and may reflect different pathomechan-
isms.20,23 Midbrain hyperechogenicity in PD seems
FIG. 1. Significantly increased area of midbrain echogenicity in the
PD group compared with the SWEDD group (P < 0.001) (broken
line: value set at 0.20 cm2 to define hyperechogenicity).
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to be a stable marker that does not change in the
course of the disease.24
TCS is a commonly available, inexpensive, and non-
invasive method without exposure to radiation, but its
application may be limited because of an inadequate
acoustic temporal bone window, particularly in older
subjects. In this study, 15.2% of subjects did not have
a sufficient bone window. This is in line with previous
studies showing that in approximately 15% of sub-
jects, midbrain structures are not assessable by
TCS.13,25
In the present study, the sensitivity of midbrain
hyperechogenicity on TCS for a diagnosis of iPD was
83% and the specificity was 90.9%, respectively. In
patients with suspected PD, hyperechogenicity indi-
cates a high probability of PD, with a positive predic-
tive value (PPV) of 93.3%.
The negative predictive value (NPV) for the diagno-
sis of SWEDD was 76.9%, indicating that absence of
hyperechogenicity would strengthen the indication for
DAT imaging.
Conclusions
We conclude that TCS is useful to distinguish
patients with PD from patients with SWEDD
and can provide additional information in patients
presenting with inconclusive parkinsonian
symptoms.
References
1. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Par-
kinson’s disease with ropinirole versus levodopa: the REALPET
study. Ann Neurol 2003;54:93–101.
2. Marek K, Seibyl J. Beta-CIT scans without evidemce of dopami-
nergic deficit (SWEDD) in the ELLDOPA-CIT and CALM-cit
study: long-term imaging assessment. Neurology 2003;60(Suppl
1):A293.
3. Marshall VL, Reininger CB, Marquardt M, et al. Parkinson’s
disease is overdiagnosed clinically at baseline in diagnostically
uncertain cases: a 3-year European multicenter study with repeat
[123I]FP-CIT SPECT. Mov Disord 2009;24:500–508.
4. Fahn S, Oakes D, Shoulson I, et al.; Parkinson Study Group. Levo-
dopa and the progression of Parkinson’s disease. N Engl J Med
2004;351:2498–2508.
5. Marek K, Jennings D, Seibyl J. Long-term follow-up of
patients with scans without evidence of dopaminergic deficit
(SWEDD) in the ELLDOPA study. Neurology 2005;64(Suppl
1):A274.
6. Schwingenschuh P, Ruge D, Edwards MJ, et al. Distinguishing
SWEDDs patients with asymmetric resting tremor from Parkin-
son’s disease: a clinical and electrophysiological study. Mov Disord
2010;25:560–569.
7. Schneider SA, Edwards MJ, Mir P, et al. Patients with adultonset
dystonic tremor resembling parkinsonian tremor have scans with-
out evidence of dopaminergic deficit (SWEDDs). Mov Disord
2007;22:2210–2215.
8. Bain PG. Dystonic tremor presenting as parkinsonism:
long-term follow-up of SWEDDs. Neurology 2009;72:
1443–1445.
9. Newman EJ, Breen K, Patterson J, Hadley DM, Grosset KA, Gros-
set DG. Accuracy of Parkinson’s disease diagnosis in 610 general
practice patients in the West of Scotland. Mov Disord 2009;24:
2379–2385.
10. Silveira-Moriyama L, Schwingenschuh P, O’Donnell A, et al.
Olfaction in patients with suspected parkinsonism and scans with-
out evidence of dopaminergic deficit (SWEDDs). J Neurol Neuro-
surg Psychiatry 2009;80:744–748.
11. Mian OS, Schneider SA, Schwingenschuh P, Bhatia KP, Day BL.
Gait in SWEDDs patients: comparison with Parkinson’s disease
and healthy controls. Mov Disord 2011;26:1266–1273.
12. Bajaj NP, Gontu V, Birchall J, Patterson J, Grosset DG, Lees AJ.
Accuracy of clinical diagnosis in tremulous parkinsonian patients:
a blinded video study. J Neurol Neurosurg Psychiatry 2010;81:
1223–1228.
13. Berg D, Godau J, Walter U. Transcranial sonography in movement
disorders. Lancet Neurol 2008;7:1044–1055.
14. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degen-
eration of substantia nigra in chronic Parkinson’s disease visualized
by transcranial color-coded real time sonography. Neurology
1995;45:182–184.
15. Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra
in Parkinson’s disease and its relation to clinical findings. J Neurol
2001;248:684–689.
16. Berg D, Becker G, Zeiler B, et al. Vulnerability of the nigrostriatal
system as detected by transcranial ultrasound. Neurology 1999;53:
1026–1031.
17. Berg D, Seppi K, Behnke S, et al. Enlarged substantia nigra hypere-
chogenicity and risk for Parkinson disease: a 37-month 3-center
study of 1847 older persons. Arch Neurol 2011;68:932–937.
18. Stockner H, Iranzo A, Seppi K, et al.; SINBAR (Sleep Innsbruck
Barcelona) Group. Midbrain hyperechogenicity in idiopathic REM
sleep behavior disorder. Mov Disord 2009;24:906–909.
19. Iranzo A, Lome~na F, Stockner H, et al. Decreased striatal dopa-
mine transporter uptake and substantia nigra hyperechogenicity
as risk markers of synucleinopathy in patients with idiopathic
rapid-eye-movement sleep behaviour disorder: a prospective
study. Lancet Neurol 2010;9:1070–1077.
20. Spiegel J, Hellwig D, M€ollers MO, et al. Transcranial sonography
and [123I]FP-CIT SPECT disclose complementary aspects of Par-
kinson’s disease. Brain. 2006;129:1188–1193.
21. Seppi K, Scherfler C, Donnemiller E, et al. Topography of dopa-
mine transporter availability in progressive supranuclear palsy: a
voxelwise [123I]beta-CIT SPECT analysis. Arch Neurol 2006;63:
1154–1160.
22. Gaenslen A, Unmuth B, Godau J, et al. The specificity and sensitiv-
ity of transcranial ultrasound in the differential diagnosis of Par-
kinson’s disease: a prospective blinded study. Lancet Neurol 2008;
7:417–424.
23. Doepp F, Plotkin M, Siegel L, et al. Brain parenchyma sonography
and 123I-FP-CIT SPECT in Parkinson’s disease and essential
tremor. Mov Disord 2008;23:405–410.
24. Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year fol-
low-up study of hyperechogenicity of the substantia nigra in Par-
kinson’s disease. Mov Disord 2005;20:383–385.
25. Stockner H Seppi K, Kiechl S, et al. Assessment of the feasibility of
midbrain sonography in a population-based study. Mov Disord
2007;22(Suppl 16):S146.
T C S D I S T I N G U I S H E S S W E D D F R O M P D
Movement Disorders, Vol. 27, No. 9, 2012 1183
